Home > Rheumatology > EULAR 2023 > EULAR 2023 Highlights Podcast

EULAR 2023 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
Conference
EULAR 2023


In this episode (21:02), Medicom’s correspondent covers 6 key updates from the annual meeting of The European Alliance of Associations for Rheumatology (EULAR 2023) held in Milan, Italy from 31 May – 3 June, 2023.

  1. Novel non-antibody fusion protein effective Sjögren’s syndrome
    In the phase 2 ALISS trial presented as a Late Breaker, dazodalibep led to a significant reduction of the symptom burden in participants with Sjögren’s syndrome. These results support further development of the drug in a phase 3 trial.
  2. HUNT study: DMARDs influence the fracture risk in RA
    In a large population-based study, rheumatoid arthritis (RA) was associated with an almost 50% increased risk of major osteoporotic fractures (MOF) compared with non-RA. However, RA treated with biological disease-modifying antirheumatic drugs (DMARDs) showed no association with MOF.
  3. Selective JAK1/TYK2 inhibition: a novel way to overcome tofacitinib resistance in RA?
    According to a Chinese trial, therapy with an investigative JAK1/TYK2 inhibitor led to remission in a third of participants with difficult-to-treat rheumatoid arthritis (RA). Novel treatment options for these patients are urgently needed.
  4. Breakthrough in patients with refractory gout: Novel 2-component infusion therapy controls serum urate levels
    In the 2 similarly designed DISSOLVE I and DISSOLVE II trials, almost 50% of patients receiving infusions with a novel 2-drug combo were able to get their serum urate concentrations under control. With this agent, anti-drug antibody responses, usually limiting the use of uricase products, are hindered by nano-encapsulated rapamycin.
  5. SSc patients with pre-capillary hypertension benefit from targeted DMARDs
    Not immunosuppressive therapy per se, but treatment with targeted therapy demonstrated a significant protective effect on mortality or worsening in patients with systemic sclerosis (SSc) and pre-capillary pulmonary hypertension (precapPH). As these new results are based on registry data, randomised-controlled trials are now suggested for further evaluation.
  6. In patients with PsA, inflammation extends to the vascular bed
    Increased vascular inflammation has been found in patients with psoriatic arthritis (PsA) compared with healthy controls. The significant differences in the target-to-background ratio (TBR) of the aorta on PET/CT pointed to the presence of vascular inflammation in PsA.




Posted on